Related Experiment Video

Updated: Jun 1, 2026

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
09:39

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

Therapeutics development in myotonic dystrophy type 1

Erin Pennock Foff1, Mani S Mahadevan

  • 1Department of Neurology, University of Virginia, Charlottesville, Virginia, USA.

Muscle & Nerve
|May 25, 2011
PubMed

Insights

Myotonic dystrophy (DM1) is a genetic disorder caused by toxic RNA. Research into RNA toxicity mechanisms offers new therapeutic strategies, including RNA-based treatments and small molecules, to combat this muscular dystrophy.

Area of Science:

  • Genetics
  • Molecular Biology
  • Neurology

Background:

  • Myotonic dystrophy (DM1) is the most common adult muscular dystrophy.
  • It is an autosomal dominant genetic disorder resulting from an expanded CTG repeat.
  • This expansion causes nuclear RNA retention and subsequent RNA toxicity, driving disease pathogenesis.

Purpose of the Study:

  • To review the clinical aspects of DM1.
  • To describe how understanding RNA toxicity pathogenesis has informed targeted therapeutic development.
  • To discuss the promise and limitations of current and emerging DM1 therapies.

Main Methods:

  • Literature review focusing on DM1 pathogenesis and therapeutic strategies.
  • Emphasis on RNA-based therapeutics and small molecules.
  • Discussion of clinical tools and outcome measures for trial evaluation.

Main Results:

  • Insights into RNA toxicity mechanisms have opened avenues for DM1 treatment.
  • Targeted therapeutic approaches are being developed at various stages of DM1 pathogenesis.
  • RNA-based therapeutics and small molecules show promise but have limitations.

Conclusions:

  • Therapeutic development for DM1 is a viable prospect due to advances in understanding RNA toxicity.
  • RNA-based and small molecule therapies are key areas of focus.
  • There is an unmet need for clinical tools and outcome measures to advance DM1 clinical trials.

More Related Videos

Assessing Functional Performance in the Mdx Mouse Model10:32

Assessing Functional Performance in the Mdx Mouse Model

Published on: March 27, 2014

Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells06:20

Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells

Published on: May 7, 2020

Related Concept Videos

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...